Goldman Sachs maintains Buy on BioMarin shares
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical Inc stock price live, this page displays NASDAQ BMRN stock exchange data. View the BMRN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biomarin Pharmaceutical Inc real time stock price chart below.
What Is the Biomarin Pharmaceutical Inc Stock Price Today?
The Biomarin Pharmaceutical Inc stock price today is 63.81.
What Is the Stock Symbol for Biomarin Pharmaceutical Inc?
The stock symbol for Biomarin Pharmaceutical Inc is "BMRN."
What Stock Exchange Does Biomarin Pharmaceutical Inc Trade On?
Biomarin Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Biomarin Pharmaceutical Inc a Good Stock to Buy?
Determining whether Biomarin Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BMRN quote. (ISIN: US09061G1013)
What Is the Biomarin Pharmaceutical Inc Stock Price Today?
The Biomarin Pharmaceutical Inc stock price today is 63.81.
What Is the Stock Symbol for Biomarin Pharmaceutical Inc?
The stock symbol for Biomarin Pharmaceutical Inc is "BMRN."
What Stock Exchange Does Biomarin Pharmaceutical Inc Trade On?
Biomarin Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Biomarin Pharmaceutical Inc a Good Stock to Buy?
Determining whether Biomarin Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BMRN quote. (ISIN: US09061G1013)
63.81
-3.18(-4.75%)
Closed
After Hours
64.18+0.37(+0.58%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
63.58
67.38
52 wk Range
61.15
94.85
BMRN Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
63.5867.38
52 wk Range
61.1594.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BMRN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
97.16
Upside
+52.27%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
14 analysts have revised their earnings downwards for the upcoming period
- Is Trump 2.0 good or bad for healthcare stocks?
- Investing.com
Pro
- Goldman Sachs maintains Buy on BioMarin shares
- Investing.com
Biomarin Pharmaceutical Inc Company Profile
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Biomarin Pharmaceutical Inc SWOT Analysis
Rare Disease Pionee | BioMarin leads in rare genetic disease therapies, with a robust portfolio and strategic focus on high-potential drugs like Voxzogo and Roctavian |
Financial Fortitude | Strong Q2 2024 performance drives raised revenue guidance to $2.75-2.83B, with ambitious plans to achieve 40%+ operating margins mid-term |
Voxzogo's Ascent | Explore Voxzogo's exceptional growth trajectory, with analysts projecting peak sales of $2.4B by 2032 and potential label expansions |
Analyst Optimism | Wall Street bullish on BioMarin, with price targets ranging from $89 to $115, reflecting confidence in the company's growth strategy and pipeline |
Biomarin Pharmaceutical Inc Earnings Call Summary for Q3/2024
- Q3 revenue up 28% to $746M, driven by 50% growth in VOXZOGO sales; 2024 guidance raised to $2.79B-$2.825B
- Restructuring into new business units for skeletal conditions, enzyme therapies, and ROCTAVIAN to improve efficiency
- Non-GAAP diluted EPS target updated to $3.25-$3.35; operating cash flow up 63% to $221M
- $495M convertible debt settled without new issuance; $1.5B cash and investments at Q3 end
- Targeting $4B revenue by 2027, 40% non-GAAP operating margin from 2026, and 11 high-impact launches by 2034
Last Updated: 31/10/2024, 09:56 am
Read Full TranscriptCompare BMRN to Peers and Sector
Metrics to compare | BMRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBMRNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 37.7x | −2.8x | −0.6x | |
PEG Ratio | 0.32 | −0.16 | 0.00 | |
Price/Book | 2.2x | 2.1x | 2.6x | |
Price / LTM Sales | 4.4x | 2.8x | 3.1x | |
Upside (Analyst Target) | 46.0% | 29.4% | 55.2% | |
Fair Value Upside | Unlock | 16.4% | 9.8% | Unlock |
Analyst Ratings
21 Buy
5 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 97.16
(+52.27% Upside)
Earnings
Latest Release
Oct 29, 2024
EPS / Forecast
0.91 / 0.53
Revenue / Forecast
746.00M / 703.14M
People Also Watch
FAQ
What Is the Biomarin Pharma (BMRN) Stock Price Today?
The Biomarin Pharma stock price today is 63.81
What Stock Exchange Does Biomarin Pharma Trade On?
Biomarin Pharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Biomarin Pharma?
The stock symbol for Biomarin Pharma is "BMRN."
What Is the Biomarin Pharma Market Cap?
As of today, Biomarin Pharma market cap is 12.16B.
What is Biomarin Pharma Earnings Per Share?
The Biomarin Pharma EPS is 1.70.
What Is the Next Biomarin Pharma Earnings Date?
Biomarin Pharma will release its next earnings report on 19 Feb 2025.
From a Technical Analysis Perspective, Is BMRN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.